{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:44:37Z","timestamp":1793965477282,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/s1470-2045(26)00378-5","type":"journal-article","created":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:52:01Z","timestamp":1793922721000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b\/2 trial"],"prefix":"10.1016","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankui","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia-Nanette","family":"Gann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(26)00378-5_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/S1470-2045(26)00378-5_bib2","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(26)00378-5_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/S1470-2045(26)00378-5_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications from pathologist's perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/S1470-2045(26)00378-5_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(26)00378-5_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib7","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(26)00378-5_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(26)00378-5_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/oncolo\/oyad025","article-title":"Variable landscape of PD-L1 expression in breast carcinoma as detected by the DAKO 22C3 immunohistochemistry assay","volume":"28","author":"Danziger","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(26)00378-5_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/S1470-2045(26)00378-5_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/S1470-2045(26)00378-5_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/417673","article-title":"Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence","volume":"2012","author":"Rossari","year":"2012","journal-title":"J Oncol"},{"key":"10.1016\/S1470-2045(26)00378-5_bib16","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(26)00378-5_bib17","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","article-title":"Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial","volume":"31","author":"Gion","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104883","article-title":"Combination of immune checkpoint inhibitors and anti-angiogenic agents: an emerging strategy for cancer therapy","volume":"215","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 1","key":"10.1016\/S1470-2045(26)00378-5_bib19","article-title":"Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327\/PM8002 shows potent antitumor activity in preclinical models","volume":"85","author":"Miao","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(26)00378-5_bib20","doi-asserted-by":"crossref","unstructured":"Guo Y, Guo J, Cheng Y, et al. Phase Ib\/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors. American Society of Clinical Oncology Annual Meeting; June 2\u20136, 2023 (abstr 2536).","DOI":"10.1200\/JCO.2023.41.16_suppl.2536"},{"issue":"suppl 2","key":"10.1016\/S1470-2045(26)00378-5_bib21","first-page":"A758","article-title":"Phase I safety and preliminary efficacy of PM8002 in subjects with advanced solid tumors, a bispecific antibody targeting PD-L1 and VEGF-A","volume":"10","author":"Ye","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/S1470-2045(26)00378-5_bib22","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(26)00378-5_bib24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(26)00378-5_bib25","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(26)00378-5_bib26","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(26)00378-5_bib28","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","volume":"37","author":"Dent","year":"2026","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/S1470-2045(26)00378-5_bib29","first-page":"PS3","article-title":"Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)","volume":"31","author":"Wang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(26)00378-5_bib30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/S1470-2045(26)00378-5_bib31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/S1470-2045(26)00378-5_bib32","doi-asserted-by":"crossref","unstructured":"Schmid P, Williams A, Aksoy S, et al. Preliminary data from a global multicohort phase 2 randomized trial of pumitamig (PD-L1 \u00d7 VEGF-A bsAb) plus chemotherapy for 1L\/2L+ locally advanced\/metastatic TNBC. San Antonio Breast Cancer Symposium; Dec 9\u201312, 2025 (abstr PS1-13-25).","DOI":"10.1158\/1557-3265.SABCS25-PS1-13-25"},{"key":"10.1016\/S1470-2045(26)00378-5_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3961\/jpmph.2012.45.2.98","article-title":"The association between serum albumin levels and metabolic syndrome in a rural population of Korea","volume":"45","author":"Cho","year":"2012","journal-title":"J Prev Med Public Health"},{"key":"10.1016\/S1470-2045(26)00378-5_bib34","doi-asserted-by":"crossref","unstructured":"Schmid RD, Razavi P, Rietschel P, et al. A global phase III, randomized, double-blind trial of Pumitamig plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01). San Antonio Breast Cancer Symposium; Dec 9\u201312, 2025 (abstr PS5-09-20).","DOI":"10.1158\/1557-3265.SABCS25-PS5-09-20"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204526003785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204526003785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:52:05Z","timestamp":1793922725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204526003785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"alternative-id":["S1470204526003785"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(26)00378-5","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b\/2 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(26)00378-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(26)00526-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}